# Imunon, Inc.: overview IMNN · Nasdaq · CIK 749647 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/imnn.md) · [Financials](/companies/imnn/financials.md) · [Filings](/companies/imnn/filings.md) · [Insiders](/companies/imnn/insiders.md) Latest reported revenue: [$125.0k](/filings/0001493152-24-011616.md) for Q4 FY2022, three months to 2022-12-31, from the 10-K filed Mar 28, 2024 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-24-011616). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(3.76)](/filings/0001493152-25-022120.md) | not reported | [(3.15)](/filings/0001493152-26-022416.md) | [(2.15)](/filings/0001493152-26-036991.md) | [(1.16)](/filings/0001493152-25-022120.md) | not reported | [(0.84)](/filings/0001493152-26-022416.md) | [(0.54)](/filings/0001493152-26-036991.md) | | Free cash flow | $k | [(4,058) d](/filings/0001493152-25-022120.md) | [(4,436) d](/filings/0001493152-26-013850.md) | [(3,107)](/filings/0001493152-26-022416.md) | [(2,969) d](/filings/0001493152-26-036991.md) | [(4,441) d](/filings/0001493152-25-022120.md) | [(3,661) d](/filings/0001493152-26-013850.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.5](/filings/0001493152-23-009604.md) | [0.5](/filings/0001493152-24-011616.md) | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(4201.4%)](/filings/0001493152-23-009604.md) | [(4984.3%)](/filings/0001493152-24-011616.md) | not reported | not reported | not reported | | Net margin | % | [(4153.9%)](/filings/0001493152-23-009604.md) | [(7179.6%)](/filings/0001493152-24-011616.md) | not reported | not reported | not reported | | Diluted EPS | $ per share | [(3.83)](/filings/0001493152-22-008277.md) | [(5.03)](/filings/0001493152-24-011616.md) | [(2.16)](/filings/0001493152-25-008460.md) | [(16.94)](/filings/0001493152-26-013850.md) | [(6.83)](/filings/0001493152-26-013850.md) | | Free cash flow | $m | [(16.5)](/filings/0001493152-23-009604.md) | [(23.4)](/filings/0001493152-24-011616.md) | [(19.5)](/filings/0001493152-25-008460.md) | [(18.9)](/filings/0001493152-26-013850.md) | [(14.2)](/filings/0001493152-26-013850.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/imnn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $257.7k | 144,767 | | Reduced −203,563 | | [Riverview Capital Advisers, LLC](/funds/1962933.md) | 2026-06-30 | $247.8k | 34,364 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $83.6k | 46,967 | | Reduced −1,089 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $56.3k | 31,629 | | Reduced −1,582 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $23.6k | 13,269 | | Unchanged | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $18.4k | 10,342 | | New +10,342 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $9.3k | 5,203 | | Added +4,628 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $7.9k | 4,464 | | Unchanged | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $7.0k | 3,952 | | Added +2,086 | | [WELLS FARGO & COMPANY/MN](/funds/72971.md) | 2026-06-30 | $5.9k | 3,342 | | Unchanged | ## Recent filings [All 1,135 filings](/companies/imnn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 06:15 ET | [S-1](/filings/0001493152-26-048630.md) | Registration statement | 0001493152-26-048630 | | 2026-10-27 | 06:05 ET | [8-K](/filings/0001493152-26-048625.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-048625 | | 2026-10-21 | 08:15 ET | [8-K](/filings/0001493152-26-047850.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-047850 | | 2026-09-29 | 08:00 ET | [8-K](/filings/0001493152-26-044792.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001493152-26-044792 | | 2026-08-11 | 17:00 ET | [8-K](/filings/0001493152-26-037170.md) | 5.02 Departure or appointment of officers or directors | 0001493152-26-037170 | | 2026-08-11 | 08:30 ET | [10-Q](/filings/0001493152-26-036991.md) | Quarterly report, period 2026-06-30 | 0001493152-26-036991 | | 2026-08-11 | 08:01 ET | [8-K](/filings/0001493152-26-036985.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-036985 | | 2026-06-30 | 16:30 ET | [8-K](/filings/0001493152-26-031292.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-031292 | | 2026-06-16 | 17:30 ET | [8-K](/filings/0001493152-26-028937.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-028937 | | 2026-06-04 | 08:00 ET | [8-K](/filings/0001493152-26-027201.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-027201 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-013850.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 749647 - Tickers: IMNN - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:17 ET. No prices; not investment advice.